Age-related osteogenic failure

Overview

Age-related osteogenic failure refers to an age-associated decline in the capacity of skeletal progenitor cells and osteoblast-lineage cells to generate new bone. In practical terms, it is a biological state in which bone formation becomes insufficient to maintain skeletal integrity, contributing to impaired bone repair, reduced bone mass, and increased susceptibility to osteoporosis and fragility fractures. The entity is most often discussed in the context of stem cell senescence, chronic inflammation, oxidative stress, and altered lineage allocation within the bone marrow niche.

Recent research frames age-related osteogenic failure as a multifactorial process rather than a single-pathway defect. Mechanistic themes include suppression of osteogenic differentiation, increased adipogenic drift of bone marrow stromal cells, mitochondrial dysfunction, autophagy imbalance, and dysregulation of signaling pathways such as AMPK/mTOR, Wnt/β-catenin, and RANKL/OPG. These studies also connect osteogenic failure to broader age-related and systemic conditions, including osteoporosis, chronic renal insufficiency, and inflammatory states.

Focus of Latest Publications

Recent publications on age-related osteogenic failure have focused on prevention, biomarker discovery, imaging-based screening, and targeted therapeutics. Several studies used multi-omic and machine-learning approaches to identify biological signals associated with osteoporosis risk, including chronic stress-related biomarkers, hub genes shared with chronic kidney disease, and plasma exosomal miR-181a-5p, which was linked to osteoporosis through endothelial-osteoblast crosstalk and bone remodeling. Another study developed a Bone Health Optimized Diet (BHOD) from UK Biobank dietary data and validated it in an external population, reporting a protective association with osteoporosis and suggesting that immune-inflammatory regulation and lipid metabolism may connect diet to bone loss.

Therapeutic innovation was also a major theme. One study engineered a bone-targeted lipid nanoparticle system to deliver anti-sclerostin antibody mRNA, using an Asp8 peptide to enhance hydroxyapatite binding and bone accumulation while reducing hepatic sequestration. In a murine ovariectomy model, this bone-directed mRNA delivery approach produced stronger effects than conventional lipid nanoparticles, stimulating bone formation, inhibiting bone resorption, and restoring trabecular bone mass and microstructure. These findings support targeted, nonhepatic mRNA-based gene editing therapeutics as a potential strategy for osteoporosis and related skeletal conditions.

Other publications addressed clinical detection and risk modification. In patients undergoing hemodialysis, computed tomography-measured trabecular attenuation at the first lumbar vertebra was independently associated with bone mineral density and showed utility as a surrogate marker for osteoporosis screening, with specific thresholds proposed for distinguishing affected from unaffected patients. A 20-year prospective observational cohort study also examined whether Helicobacter pylori eradication might protect against osteoporosis in females, reflecting interest in infection-related prevention strategies, although the abstract provided here does not state the study’s outcome.

Key Publications

NEWJul BHOD: a bone health optimized dietary pattern designed for osteoporosis prevention. (NPJ science of food, 2026, PMID 42386741): "We aimed to develop a Bone Health Optimized Diet (BHOD) that is tailored to more precisely reduce the risk of osteoporosis."
NEWJul Engineering Bone-Targeted LNP Delivery of Anti-Sclerostin Antibody mRNA for the Treatment of Osteoporosis. (Journal of biomedical materials research. Part A, 2026, PMID 42338194): "This system enables efficient expression of anti-sclerostin antibody mRNA in bone tissue, thereby achieving therapeutic effects for osteoporosis treatment."
NEWJun Identification of Chronic Stress-Related Biomarkers for Potential Diagnosis and Treatment of Osteoporosis: An Integrated Multi-omic and Clinical Data Analysis. (Therapeutic innovation & regulatory science, 2026, PMID 42265416): "The mechanisms through which chronic stress-related genes influence the diagnosis of osteoporosis (OP), where chronic stress serves as a risk factor, remain unclear."
May Computed tomography-measured trabecular attenuation at first lumbar vertebra as a surrogate marker of bone mineral density and osteoporosis in patients undergoing hemodialysis. (Renal failure, 2026, PMID 42161888): "We examined the association between computed tomography (CT)-measured trabecular attenuation at the first lumbar vertebra (L1 CT-attenuation), bone mineral density (BMD), and osteoporosis in patients on hemodialysis."
May Identification of potential biomarkers for osteoporosis and chronic kidney disease through bioinformatics and machine learning algorithm. (PloS one, 2026, PMID 42081554): "to identify hub genes associated with both osteoporosis (OP) and chronic kidney disease (CKD) through bioinformatics analysis"
May Plasma exosomal miR-181a-5p is linked to osteoporosis by mediating endothelial-osteoblast crosstalk and regulating bone remodeling. (Biochemical and biophysical research communications, 2026, PMID 41894988): "To elucidate the correlation between plasma exosomal miR-181a-5p and osteoporosis (OP)."
May Preventive Effect of Helicobacter pylori Eradication on Osteoporosis in Females: A 20-Year Prospective Observational Cohort Study. (Gut and liver, 2026, PMID 40820207): "This study aimed to ascertain whether HP eradication therapy confers protective effects against osteoporosis progression."